Company Description
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC.
and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Country | United States |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 838 |
| CEO | Jack Khattar |
Contact Details
Address: 10710 Midlothian Turnpike, Suite 125 North Chesterfield, Virginia 23235 United States | |
| Phone | 804 379 1040 |
| Website | indivior.com |
Stock Details
| Ticker Symbol | SPUN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1625297 |
| Employer ID | 41-2520873 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jack Khattar | Chief Executive Officer |
| Timothy Dec | Chief Financial Officer |
| Jason Thompson | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 2, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 425 | Filing |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 6, 2026 | 425 | Filing |
| Oct 6, 2026 | 8-K | Current Report |
| Sep 30, 2026 | SCHEDULE 13G | Filing |
| Sep 17, 2026 | 425 | Filing |
| Sep 17, 2026 | 8-K | Current Report |